Structural interventions
for treatment-resistant
depression & OCD.
We do not offer 'wellness'. We provide precision neurostimulation (TMS), quantitative EEG mapping, and targeted neuroplasticity protocols backed by clinical trial data, not marketing copy.
Clinic Baseline Efficacy
The standard model fails 30% of patients.
Selective Serotonin Reuptake Inhibitors (SSRIs) and traditional talk therapy form the baseline of psychiatric care. Yet, STAR*D trial data demonstrates that the likelihood of remission drops sharply after two failed medication trials.
If you are reading this, you likely fall into the treatment-resistant category. Doing more of the same—switching from Escitalopram to Sertraline, or changing therapists—is statistically unlikely to yield remission. You require a structural, localized intervention.
-
Systemic Side Effects Medications affect the entire body, causing weight gain, insomnia, and sexual dysfunction.
-
Targeted Neuromodulation TMS uses magnetic fields to specifically target the left dorsolateral prefrontal cortex (DLPFC), bypassing the systemic bloodstream entirely.
Clinical Protocols
Transcranial Magnetic Stimulation (TMS)
FDA-cleared for Major Depressive Disorder and OCD. Utilizes MRI-strength magnetic pulses to stimulate underactive neural circuits.
- Duration: 36 sessions
- Session Time: 19-37 mins
- Coverage: Most major insurers
Quantitative EEG (qEEG) Mapping
Functional brain imaging measuring electrical activity across 19 surface locations to identify dysregulated networks and inform targeting.
- Duration: 1 session
- Analysis: Z-score database
- Output: Topographic maps
Clinical Neurofeedback
Operant conditioning of brainwaves based on qEEG data. Used primarily for ADHD, PTSD, and generalized anxiety disorder.
- Duration: 20-40 sessions
- Mechanism: Plasticity
- Status: Out-of-pocket
Clinical Outcomes vs Control
Data derived from Carpenter et al. (2012) and internally audited patient records (2020-2023) for MDD patients failing >2 adequate medication trials.
| Intervention | Response Rate (≥50% drop) | Remission Rate (<5 score) | Systemic Side Effects |
|---|---|---|---|
| SSRI (3rd Trial - STAR*D) | 16.2% | 13.7% | High (Weight, Libido) |
| Standard rTMS (DLPFC) | 58.0% | 37.1% | Low (Scalp discomfort) |
| Our Clinic (qEEG-Guided TMS) | 71.2% | 44.8% | Low |
Patient Assessment Tools
Use these validated clinical calculators to establish baselines before consultation. No data is saved to our servers; computation happens strictly on your device.
01 / The Paradigm
Mental health is a physical problem. It requires a physical intervention.
The brain is an electrochemical organ. When specific neural networks—such as the Default Mode Network (DMN) or the dorsolateral prefrontal cortex (DLPFC)—become dysregulated, talking about it is insufficient. Chemical interventions (SSRIs) flood the entire system, producing systemic side effects for localized problems.
We treat the brain as a machine that can be calibrated. Using targeted magnetic fields, we induce plasticity exactly where the qEEG map indicates a deficit. This is not therapy. This is engineering applied to the human cortex.
The Plasticity Window
Inducing BDNF
Brain-Derived Neurotrophic Factor (BDNF) is the protein responsible for neuroplasticity. TMS directly forces the release of BDNF in the targeted cortex.
The goal of a 36-session TMS protocol is not temporary symptom relief. The goal is to force a localized spike in BDNF, opening a "plasticity window." During this window, the brain structurally rewires itself, strengthening the synaptic connections that regulate mood and executive function.
The Clinical Journey
Mapping & Thresholding
qEEG baseline established. Motor threshold determined to calibrate magnetic pulse intensity to your specific physiology.
Acute Phase (Daily)
Five days a week, 19 minutes a day. The "plasticity window" opens. Patients often report vivid dreams and shifts in sleep architecture.
Consolidation Phase
Synaptic connections solidify. Most patients register a >50% drop in PHQ-9 scores by the end of week 5.
Taper & Remission
Sessions step down to 3x, then 2x a week. Final exit mapping performed. Protocol concludes.
Who we do not treat.
We reject 18% of applicants during intake. This intervention is powerful, and it is not for everyone. We will not take your money if the data indicates you are not a candidate.
- Active Substance Use Disorder (affects seizure threshold)
- History of Epilepsy or uncontrolled seizures
- Non-removable ferromagnetic metal in the head
- Untreated Bipolar Disorder (Type I) without mood stabilizers
Hardware Specifications
We utilize the Magstim Horizon 3 performance system with a figure-8 coil, capable of delivering a 2.0 Tesla magnetic field. This is the exact hardware profile utilized in the pivotal FDA clearance trials.
Primary Literature
Updated Q3 2023Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Depression.
A large-scale meta-analysis demonstrating the statistical superiority of high-frequency left DLPFC stimulation over sham.
PubMed ID: 29800020Accelerated iTBS (Stanford Neuromodulation Therapy).
Demonstrated a 90% remission rate in highly refractory patients using multiple daily doses guided by fMRI.
PubMed ID: 32247028Deep TMS for Obsessive-Compulsive Disorder.
Results from the multicenter double-blind randomized controlled trial leading to FDA clearance for OCD.
PubMed ID: 31450957Clinical Case Report: 0042
Patient Profile
- Age/Sex: 34, Female
- Diagnosis: Severe MDD (F33.2), GAD
- Failed Meds: Sertraline, Bupropion, Venlafaxine
- Duration of episode: 18 months
Patient presented with severe anhedonia and psychomotor retardation. qEEG mapping indicated severe frontal alpha asymmetry. Initiated standard 36-session left-DLPFC high-frequency protocol.
PHQ-9 Trajectory
The Intake Process
Pre-Screening
Submit your medication history and baseline PHQ-9. We verify insurance eligibility within 48 hours.
Psychiatric Evaluation
A 60-minute consult with our medical director to confirm diagnosis and clear contraindications.
Mapping & Protocol
Motor threshold mapping is performed, and daily sessions begin immediately following.
Stop iterating on failed medications.
If you have failed two or more antidepressants, the probability of the third working is less than 15%. Change the modality.
Transparent Financials
We do not hide our fee structure behind a sales call. If you are paying entirely out-of-pocket, here is exactly what it costs.
Complete TMS Course
Mapping + 36 Sessions
- Initial psychiatric evaluation
- Motor threshold mapping
- 36 daily sessions (approx 6-7 weeks)
If you have major commercial insurance (Aetna, BCBS, Cigna, UHC) and have failed 2-4 antidepressants, your out-of-pocket is typically limited to your specialist co-pay ($30-$60/session).